OncoGenex Pharmaceuticals, Inc. Message Board

Another ophthalmology company, Sucampo Pharmaceuticals, Inc. (SCMP) - a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones - announced that the Japan Science and Technology Agency (JST) has adopted unoprostone isopropyl ophthalmic solution .15% in the Adaptable and Seamless Technology Transfer Program. As part of this program, R-Tech Ueno, Sucampo's development partner shall provide most of funding for Phase III clinical development of unoprostone isopropyl for retinitis pigmentosa (RP) - a genetic disease characterized by progressive, irreversible vision loss. There are no drugs or therapeutic procedures currently approved for the treatment of RP today. Currently, the FDA has granted orphan drug designation to unoprostone isopropyl for treatment of RP.

This project is the only one out of 17 that was selected for this prestigious Technology Transfer Program. The agreement also provides Sucampo with the clinical data needed to file for an RP indication in the US and Europe, an important step in treating other ophthalmic diseases.

sell the drug directly to Abbott at a whole sale price. This means that they will book revenues directly, at lets say 80%. This is much better than the 18% royalties from Takeda in the US. Japan is the second most prescribing country in the world. This is a huge market

There have been 7 million scrips written for Amitiza, so safety concerns are zero.

Had to let that be know.

Yes, Sucampo will sell Amitiza to Abbott in Japan wholesale.. This means they will book this as sales (est 70% )of the retail price. This means the margins will be HUGE.

I expect this will continue..

eom...

eom..

Sorry it had to be this way..

eom..

Look like anyway..

We will see in about one week..

What a day....

She did right on schedule..

Seen this all before..

Less than a few days and we will see this priced at $5.50

I do have some furthr information..